Table 4

Sensitivity of surveillance modalities in detecting pancreatic abnormalities

Abnormality on imagingTotal*, NEUSMRI/MRCPEUS vs MRI/MRCP
P value
EUS vs
EUS+MRI/MRCP
P value
MRI/MRCP vs
EUS+MRI/MRCP
P value
Solid lesions25100% (22/22)22% (4/18)<0.001NA<0.001
Indeterminate lesions†3661% (22/36)54% (19/35)0.85<0.001<0.001
Cystic lesions46342% (187/446)83% (376/455)<0.001<0.001<0.001
 ≥10 mm3870% (26/37)92% (34/37)0.060.0010.25
 <10 mm42439% (161/409)82% (342/418)<0.001<0.001<0.001
 With solid component or mural nodule5100% (4/4)20% (1/5)0.13NA0.13
Main pancreatic ducts 5–9 mm‡2162% (13/21)60% (12/20)>0.990.010.01
Pancreatic neuroendocrine tumours6100% (6/6)33% (2/6)0.13NA0.13
  • Sensitivity was assessed at the first detection of the abnormality. The total number of abnormalities per modality (in brackets) differ if one of the modalities had not been performed at that specific visit.

  • *The used reference standard was presence of the abnormality on either EUS, MRI/MRCP or CT; only for neuroendocrine tumours the diagnosis was based on cytological or histological confirmation.

  • †Hypoechoic or hypointense lesions of unknown significance that could not with certainty be classified as solid or cystic at diagnosis.

  • ‡With or without the presence of a focal lesion.

  • EUS, endoscopic ultrasonography; MRI/MRCP, MRI/magnetic resonance cholangiopancreatography; NA, not applicable because sensitivity was 100% with and without performing MRI/MRCP; PDAC, pancreatic ductal adenocarcinoma.